Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 8974 results

  1. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Magtrace/Sentimag MT599 (MIB263)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis

    Awaiting development Reference number: GID-HTG10536 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    In development Reference number: GID-HTG10172 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  9. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Neonatal infection: antibiotics for prevention and treatment - update

    In development Reference number: GID-NG10456 Expected publication date:  13 May 2026

    NICE guideline
    In development

  15. Epilepsies in children, young people and adults

    In development Reference number: GID-NG10453 Expected publication date: TBC

    NICE guideline
    In development